StrongDecrease
All-cause mortality
Multifactorial Therapy (MT) → All-cause mortality
Multifactorial Therapy (MT) → All-cause mortality
Evidence profile
StrongDecreaseClinical Outcomes
Unlock full evidence details
Research Summary
Analyzed using Evidence Intelligence™
Intensive multifactorial therapy reduces mortality risk in women with diabetes
Key finding
The reduction in mortality risk by MT was greater in women (44% versus 12%, P = 0.019).
This study analyzed the effects of Multifactorial Therapy (MT) versus Usual Care (UC) in participants with type 2 diabetes, finding significant reductions in major adverse cardiovascular events and all-cause mortality.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
High bias
Last updated July 6, 2026Quick read
Study at a glance
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Multifactorial Therapy (MT), Usual Care (UC)
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
Major Adverse MACEs
Comparator
Usual Care (UC)
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study analyzed the effects of Multifactorial Therapy (MT) versus Usual Care (UC) in participants with type 2 diabetes, finding significant reductions in major adverse cardiovascular events and all-cause mortality.
Clinical relevance
These findings highlight the potential of Multifactorial Therapy in improving health outcomes for individuals with type 2 diabetes, especially among women. By reducing both cardiovascular events and mortality, MT could lead to better long-term health and quality of life for this population.
Keep in mind
The study was a post-hoc analysis, which may limit the strength of conclusions. Results may not be generalizable to all populations with type 2 diabetes. Effectiveness measures were unclear for some outcomes.
Published in
Journal Reference
Publication details and source links for this paper.
Roberto M, Vittorio S, Luca DN, et al. Post-hoc analysis of the Nephropathy In Diabetes type 2 study. Cardiovascular Diabetology. 2024;23:285. doi:10.1186/s12933-024-02371-3
Save this study and add notes to your research library.
Main Effects
MT reduced the risk of major adverse cardiovascular events by 52% in women and 44% in men (P = 0.11).
MT led to a 44% reduction in all-cause mortality for women compared to 12% for men (P = 0.019).
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Multifactorial Therapy (MT), Usual care and All-cause mortality, Cardiovascular events.
This study contributes evidence to
Primary intervention
Multifactorial Therapy (MT)
Primary outcomes
- All-cause mortality
- Cardiovascular events
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
4
Evidence pairs
4
Relationships
1
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 59
1
Related topics
4
Evidence pairs
33
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 4 evidence relationships
- Includes primary outcome data
- Linked to 1 direct semantic evidence topic
Topic contributions
Evidence topic
Contributes evidence
Core evidence
Study findings
The primary outcomes reported in this study.
NoneDecrease
Cardiovascular events
Multifactorial Therapy (MT) → Cardiovascular events
Multifactorial Therapy (MT) → Cardiovascular events
Evidence profile
NoneDecreaseClinical Outcomes
Unlock full evidence details
NoneNo Change
All-cause mortality
Usual care → All-cause mortality
Usual care → All-cause mortality
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
NoneNo Change
Cardiovascular events
Usual care → Cardiovascular events
Usual care → Cardiovascular events
Evidence profile
NoneNo ChangeClinical Outcomes
Unlock full evidence details
Unlock full evidence analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- MT reduced MACE risk by 52% in women and 44% in men.
- MT decreased all-cause mortality risk by 44% in women compared to 12% in men.
Who this applies to
- Adults diagnosed with type 2 diabetes.
- Individuals at risk for cardiovascular events.
Keep in Mind
- The findings are based on a specific study population and may not apply broadly.
- The statistical significance of some outcomes was not strong (P = 0.11).
- Further research is needed to confirm these findings in diverse populations.
Between the Lines
- The study was a post-hoc analysis, which may limit the strength of conclusions.
- Results may not be generalizable to all populations with type 2 diabetes.
- Effectiveness measures were unclear for some outcomes.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Multifactorial Therapy (MT) and Cardiovascular Outcomes.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Cardiovascular Outcomes Evidence Hub
All studies measuring Cardiovascular Outcomes
1 studies
outcome_hubMeasures Cardiovascular Outcomes as a key outcome.
Multifactorial Therapy (MT) Evidence Hub
All studies on Multifactorial Therapy (MT)
1 studies
intervention_hubContributes to Multifactorial Therapy (MT) evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Multifactorial Therapy (MT) and All-cause mortality
Intervention: Multifactorial Therapy (MT)Outcome: All-cause mortality
1 results
All studies on Multifactorial Therapy (MT)
Intervention: Multifactorial Therapy (MT)
1 results
All studies measuring All-cause mortality
Outcome: All-cause mortality
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Multifactorial Therapy (MT) improve all-cause mortality?
Emerging Evidence
Multifactorial Therapy (MT) appears to improve All-cause mortality.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Emerging | EvidenceScore™ 50.6 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Multifactorial Therapy (MT) improve cardiovascular events?
Limited Evidence
Current evidence does not show a clear benefit of Multifactorial Therapy (MT) for Cardiovascular events.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Cardiovascular events
EvidenceScore™ Limited | EvidenceScore™ 33.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Usual care improve all-cause mortality?
Limited Evidence
Current evidence does not show a clear benefit of Usual care for All-cause mortality.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
All-cause mortality
EvidenceScore™ Limited | EvidenceScore™ 33.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Does Usual care improve cardiovascular events?
Limited Evidence
Current evidence does not show a clear benefit of Usual care for Cardiovascular events.
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Cardiovascular events
EvidenceScore™ Limited | EvidenceScore™ 33.1 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
- Consistency cannot yet be determined.
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Digital intervention improves glycemic control in type 2 diabetes patientsTelemonitoring improves glycemic control in pediatric diabetesPeer-Created Videos Improve Psychological Outcomes in Type 1 DiabetesDiabetes APP may improve blood glucose control in T2DM patientsSemaglutide improves cardiovascular outcomes in high-risk patients
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.